|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Skyrizi
|
|
gptkbp:activities
|
IL-23 inhibition
|
|
gptkbp:approves
|
gptkb:2019
|
|
gptkbp:care_instructions
|
dilute with sterile water for injection
|
|
gptkbp:class
|
immunomodulator
|
|
gptkbp:clinical_trial
|
gptkb:unknown
Phase 3
NC T03104365
NC T03374864
NC T03374877
NC T03374890
NC T03425075
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to risankizumab
|
|
gptkbp:developed_by
|
gptkb:Abb_Vie
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:formulation
|
lyophilized powder for reconstitution
|
|
gptkbp:frequency
|
every 12 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
risankizumab-rzaa
|
|
gptkbp:indication
|
moderate to severe plaque psoriasis
moderate to severe ulcerative colitis
moderate to severe Crohn's disease
|
|
gptkbp:ingredients
|
gptkb:risankizumab
C6420 H9924 N1716 O1980 S44
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
psoriasis
|
|
gptkbp:lifespan
|
approximately 28 days
|
|
gptkbp:manager
|
subcutaneous injection
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
reduces IL-23 levels
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
thrombosis
injection site reactions
upper respiratory infections
serious infections
malignancies
|
|
gptkbp:storage
|
2 to 8 ° C
|
|
gptkbp:targets
|
gptkb:interleukin-23
|
|
gptkbp:traded_on
|
gptkb:Skyrizi
|
|
gptkbp:website
|
upper arm
thigh
abdomen
|
|
gptkbp:weight
|
146 k Da
|